- Home
- ATYR
as 10-29-2025 9:37am EST
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 105.8M | IPO Year: | 2015 |
| Target Price: | $8.88 | AVG Volume (30 days): | 8.3M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $7.29 | Next Earning Date: | 11-11-2025 |
| Revenue: | N/A | Revenue Growth: | -33.43% |
| Revenue Growth (this year): | 420.85% | Revenue Growth (next year): | 1513.40% |
Latest aTyr Pharma Inc. Common Stock News
ATYR Breaking Stock News: Dive into ATYR Ticker-Specific Updates for Smart Investing
Simply Wall St.
17 days ago
Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares
Insider Monkey
2 months ago
Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results
GlobeNewswire
2 months ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
4 months ago
Sector Update: Health Care Stocks Increase in Afternoon Trading
GlobeNewswire
4 months ago
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
Simply Wall St.
4 months ago
With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing
GlobeNewswire
5 months ago
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Simply Wall St.
5 months ago
High Growth Tech Stocks in the US to Watch This May 2025
Compare ATYR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATYR aTyr Pharma Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.